<div id="readability-page-1"><p>Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) CFO Maged Shenouda acquired 11,665 shares of the stock in a transaction on Monday, December 15th. The shares were purchased at an average price of $4.12 per share, for a total transaction of $48,059.80. Following the completion of the transaction, the chief financial officer owned 800,000 shares in the company, valued at approximately $3,296,000. This represents a 1.48% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.</p><div><p><span></span><span>Get <strong>Relmada Therapeutics</strong> alerts:</span></p></div><p>Maged Shenouda also recently made the following trade(s): </p><ul><li>On Wednesday, November 5th, Maged Shenouda acquired 500,000 shares of Relmada Therapeutics stock. The shares were acquired at an average price of $2.20 per share, with a total value of $1,100,000.00. </li></ul><h2>Relmada Therapeutics Stock Performance</h2><p>RLMD stock opened at $4.71 on Tuesday. The firm has a 50 day simple moving average of $3.21 and a 200 day simple moving average of $1.75. Relmada Therapeutics, Inc. has a 52 week low of $0.24 and a 52 week high of $5.12. The stock has a market cap of $345.11 million, a P/E ratio of -2.63 and a beta of 0.74. </p><p>Relmada Therapeutics (NASDAQ:RLMD - Get Free Report) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.26).  Sell-side analysts predict that  Relmada Therapeutics, Inc. will post -2.73 EPS for the current year. </p><h2>Institutional Investors Weigh In On Relmada Therapeutics</h2><p>Several hedge funds and other institutional investors have recently modified their holdings of RLMD. Goldman Sachs Group Inc. bought a new position in  Relmada Therapeutics during the first quarter worth $33,000.  AdvisorShares Investments LLC grew its position in  Relmada Therapeutics by 43.4% in the 2nd quarter. AdvisorShares Investments LLC now owns 396,514 shares of the company's stock worth $238,000 after purchasing an additional 120,000 shares during the last quarter.  Marshall Wace LLP acquired a new stake in  Relmada Therapeutics in the 2nd quarter worth $93,000.  Corient Private Wealth LLC acquired a new stake in  Relmada Therapeutics during the second quarter worth about $120,000.  Finally, Two Sigma Investments LP increased its stake in  Relmada Therapeutics by 82.0% during the third quarter. Two Sigma Investments LP now owns 173,614 shares of the company's stock valued at $349,000 after acquiring an additional 78,197 shares during the period. Institutional investors and hedge funds own  45.24% of the company's stock. </p><h2>Wall Street Analyst Weigh In</h2><p>Several brokerages have recently commented on RLMD. Weiss Ratings  restated a &#34;sell (e+)&#34; rating on shares of Relmada Therapeutics in a research note on Friday, October 31st. Mizuho raised shares of Relmada Therapeutics from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and increased their target price for the stock from $1.00 to $10.00 in a research report on Wednesday, November 19th. Finally, Wall Street Zen raised Relmada Therapeutics to a &#34;hold&#34; rating in a research report on Saturday, October 11th. One research analyst  has rated the stock with a Buy rating and one  has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of &#34;Hold&#34; and a consensus target price of $10.00.</p><p><b>View Our Latest Stock Analysis on RLMD</b></p><h2>About Relmada Therapeutics</h2> (Get Free Report)<p>Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.</p><h2>See Also</h2><ul><li>Five stocks we like better than Relmada Therapeutics</li><li>The 3 Best Fintech Stocks to Buy Now</li><li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li><li>Best Stocks Under $5.00</li><li>Unassuming Evergy Energy: The AI Boost Your Income Portfolio Needs</li><li>Profitably Trade Stocks at 52-Week Highs</li><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxNRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxNRA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Relmada Therapeutics Right Now?</h2><p>Before you consider Relmada Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relmada Therapeutics wasn't on the list.</p><p>While Relmada Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

RLMD

<p>Relmada Therapeutics CFO Maged Shenouda purchased 11,665 shares at $4.12 each, totaling $48,059.80. Post-transaction, he owns 800,000 shares valued at $3,296,000, a 1.48% increase. The transaction was disclosed in an SEC filing. Shenouda also bought 500,000 shares on November 5th at $2.20 each, totaling $1,100,000. RLMD stock opened at $4.71 on Tuesday. The company reported a Q3 loss of $0.30 per share. Institutional investors hold 45.24% of RLMD. Analysts have mixed ratings on the stock.</p>

Relmada Therapeutics (NASDAQ:RLMD) CFO Buys $48,059.80 in Stock